Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High?

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) has seen a 14.9% increase in share price over the past four weeks, closing at $7.88, with a potential upside of 408.6% based on Wall Street analysts' mean price target of $40.08 [1] Price Targets and Estimates - The mean estimate consists of 25 short-term price targets with a standard deviation of $26.66, indicating variability among analysts; the lowest estimate is $9 (14.2% increase), while the highest is $106 (1245.2% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts show strong agreement in revising NTLA's earnings estimates higher, which correlates with potential stock price increases; the Zacks Consensus Estimate for the current year has risen by 7.6% over the last 30 days [4][11][12] - NTLA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a solid potential upside [13]